Joint application of dihydrotanshinone I and protocatechualdehyde to preparation of medicines for treating acute myocardial infarction

A technology of acute myocardial infarction and dihydrotanshinone, which is applied in the field of medicine, can solve problems such as strong cytotoxicity, and achieve the effects of improving the therapeutic effect, reducing the size of myocardial infarction, and maintaining long-lasting drug effects

Inactive Publication Date: 2017-02-22
CHINA PHARM UNIV
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there are also research reports that dihydrotanshinone I has strong cytotoxicity [Cytotoxicity of major tanshinones isolated f

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Joint application of dihydrotanshinone I and protocatechualdehyde to preparation of medicines for treating acute myocardial infarction
  • Joint application of dihydrotanshinone I and protocatechualdehyde to preparation of medicines for treating acute myocardial infarction
  • Joint application of dihydrotanshinone I and protocatechualdehyde to preparation of medicines for treating acute myocardial infarction

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] Embodiment 1: the attenuation effect of protocatechualdehyde to dihydrotanshinone I

[0025] 1. Experimental materials

[0026] 1.1 Instruments and equipment

[0027] Ultra-clean bench (Thermo Scientific 1300A2, USA); multifunctional microplate reader FLUOstar Omega (BMG LABTECH, Germany); electronic scale (Tianjin Tianma Hengji Instrument Co., Ltd.); Sartorius analytical balance (Beijing Doris Balance Co., Ltd.); BL -420S biological function experiment system (Chengdu Taimeng Technology Co., Ltd.); HX-100E small animal ventilator (Chengdu Taimeng Technology Co., Ltd.); HW-1000 water bath (Chengdu Taimeng Technology Co., Ltd.).

[0028] 1.1 Reagents

[0029] Standard products: dihydrotanshinone I and protocatechualdehyde were purchased from Chengdu Mansite Biotechnology Co., Ltd.

[0030] Reagents: DMEM high glucose medium, fetal bovine serum, 100× penicillin and streptomycin (Thermo Fisher, USA); type II collagenase (Worthington, USA); 5-bromodeoxyuridine (sigma, ...

Embodiment 2

[0091] Embodiment 2: the synergistic effect of protocatechualdehyde and dihydrotanshinone I

[0092] 1.1 Instruments and equipment

[0093] Multifunctional microplate reader FLUOstar Omega (BMG LABTECH, Germany); 80-2 desktop low-speed centrifuge (Shanghai Medical Instrument (Group) Co., Ltd. Surgical Instrument Factory); 5804R desktop refrigerated high-speed centrifuge (Eppendorf, Germany); Sartorius analysis Balance (Beijing Doris Balance Co., Ltd.) electronic scale (Tianjin Tianma Hengji Instrument Co., Ltd.); Sartorius analytical balance (Beijing Doris Balance Co., Ltd.); BL-420S biological function experiment system (Chengdu Taimeng Technology Co., Ltd.); HX- 100E small animal ventilator (Chengdu Taimeng Technology Co., Ltd.); HW-1000 water bath (Chengdu Taimeng Technology Co., Ltd.).

[0094] 1.2 Reagents

[0095] Standard products: dihydrotanshinone I, protocatechualdehyde, all purchased from Chengdu Mansite.

[0096] Reagents: urethane (Sinopharm Chemical Reagent ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses joint application of dihydrotanshinone I and protocatechualdehyde to preparation of medicines for treating acute myocardial infarction and particularly provides a medicine for treating acute myocardial infarction. Active components of the medicine include dihydrotanshinone I and protocatechualdehyde. A pharmaceutical preparation for treating acute myocardial infarction comprises the active components and a pharmaceutically acceptable carrier or excipient and is made into a pharmaceutically acceptable form. The joint application has advantages that toxicity of dihydrotanshinone I is reduced while efficacy advantages of the dihydrotanshinone I are achieved, namely myocardial infarction area of acute myocardial infarction rats can be effectively reduced, long drug action is realized, and toxic lethality is evidently decreased. Further, treatment effects of the dihydrotanshinone I on the myocardial infarction rats can be evidently improved by addition of protocatechualdehyde in different doses, and the dihydrotanshinone I and the protocatechualdehyde have an efficacy synergistic effect.

Description

technical field [0001] The invention belongs to the field of medicine, and relates to the combined medicine of known chemical components, in particular to the application of dihydrotanshinone I and protocatechualdehyde in the preparation of medicine for treating acute myocardial infarction. Background technique [0002] Acute myocardial infarction (AMI) is the most serious coronary artery disease, accounting for one-third of the annual deaths in developed countries. In the United States, more than 2.4 million people died of myocardial infarction, and in Europe and northern Asia, more than 4 million people died of myocardial infarction [Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19 1 million participants, Lancet. 2016 Nov 15.pii:S0140-6736(16)31919-5]. In recent decades, percutaneous coronary intervention or thrombolytic therapy has been used to reduce the mortality rate of coronary heart disease....

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/58A61K31/11A61P9/10
CPCA61K31/11A61K31/192A61K31/343A61K31/58A61K2300/00
Inventor 李萍蒋黎锋倪丽红祁励丰荣夏露丹曾昊刘可
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap